^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TAK-007

    i
    Other names: TAK-007, TAK007, TAK 007, Anti-CD19 CAR NK-cell therapy, iC9/CAR.19/IL15-Transduced CB-NK Cells
    Associations

    News

    Trials
    Company:
    Takeda, UT MD Anderson Cancer Center
    Drug class:
    CD19 inhibitor
    Related drugs:
    Associations

    News

    Trials
    19d
    A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Takeda | Initiation date: Nov 2024 --> May 2025
    Trial initiation date
    |
    cyclophosphamide • TAK-007
    7ms
    A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, Takeda | N=265 --> 27 | Recruiting --> Active, not recruiting
    Enrollment closed • Enrollment change
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • TAK-007
    8ms
    A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Takeda
    New P1 trial
    |
    cyclophosphamide • TAK-007
    10ms
    A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
    P2, N=265, Recruiting, Takeda | Trial completion date: Oct 2029 --> Jun 2030 | Trial primary completion date: Oct 2029 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • TAK-007
    3years
    A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
    P2; N=242; Recruiting; Sponsor: Takeda; Not yet recruiting ➔ Recruiting
    Enrollment open • Clinical
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • TAK-007
    over3years
    A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) (clinicaltrials.gov)
    P2, N=242, Not yet recruiting, Takeda
    Clinical • New P2 trial
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    TAK-007